Axon Enterprise Inc. has experienced a significant decline in its stock price, dropping 40.9% from its 52-week high and falling 17.5% year-to-date, which contrasts sharply with the Nasdaq's 11.8% gain over the same period. This underperformance is primarily driven by investor concerns regarding potential dilution stemming from a recent capital raise. To address liquidity needs, the company has initiated an offering of convertible notes totaling $1 billion. Market participants are worried that this substantial issuance could lead to significant share dilution, especially given the current state of the company's cash balance which is reportedly falling. These factors have collectively weighed heavily on investor sentiment and stock valuation. The market reaction highlights the sensitivity of Axon Enterprise's equity value to its capital structure decisions. The combination of a large convertible note offering and a declining cash position has created a narrative of financial stress, causing the stock to lag significantly behind broader technology sector benchmarks.